BMS-986234
/ BMS
- LARVOL DELTA
Home
Next
Prev
1 to 2
Of
2
Go to page
1
February 01, 2022
Mechanism of hepatobiliary toxicity of the LPA antagonist BMS-986020 developed to treat idiopathic pulmonary fibrosis: Contrasts with BMS-986234 and BMS-986278.
(PubMed, Toxicol Appl Pharmacol)
- "The data indicate that this toxicity was unrelated to LPA antagonism since the mechanisms that likely influenced the adverse clinical outcome of BMS-986020 were not observed with equipotent LPA antagonists BMS-986234 and BMS-986278. This conclusion is consistent with the lack of hepatobiliary toxicity in nonclinical and clinical safety studies with BMS-986278."
Journal • Fibrosis • Gastroenterology • Hepatology • Idiopathic Pulmonary Fibrosis • Immunology • Pulmonary Disease • Respiratory Diseases • ABCC3
January 04, 2022
Structure dependence and species sensitivity of in vivo hepatobiliary toxicity with lysophosphatidic acid receptor 1 (LPA) antagonists.
(PubMed, Toxicol Appl Pharmacol)
- "BMS-986020, BMS-986234 and BMS-986278, are three lysophosphatidic acid receptor 1 (LPA) antagonists that were or are being investigated for treatment of idiopathic pulmonary fibrosis (IPF). Mixed effects on plasma bile acids in both rat and monkey has made this biomarker not a useful predictor of the hepatobiliary toxicity. In conclusion, the nonclinical data indicate the hepatobiliary toxicity observed clinically and in monkeys administered BMS-986020 is compound specific and not mediated via antagonism of LPA."
Journal • Preclinical • Cholestasis • Developmental Disorders • Fibrosis • Gastroenterology • Hepatology • Idiopathic Pulmonary Fibrosis • Immunology • Pulmonary Disease • Respiratory Diseases
1 to 2
Of
2
Go to page
1